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Doxazosin, a drug commonly prescribed for hypertension and prostate disease,
increases heart failure risk. However, the underlying mechanism remains unclear.
Galectin-3 is an important mediator that plays a pathogenic role in cardiac hypertrophy
and heart failure. In the present study, we investigated whether doxazosin could
stimulate galectin-3 expression and collagen synthesis in cultured HL-1 cardiomyocytes.
We found that doxazosin dose-dependently induced galectin-3 protein expression,
with a statistically significant increase in expression with a dose as low as 0.01 µM.
Doxazosin upregulated collagen I and α-smooth muscle actin (α-SMA) protein levels
and also induced apoptotic protein caspase-3 in HL-1 cardiomyocytes. Although we
previously reported that activation of protein kinase C (PKC) stimulates galectin-3
expression, blocking the PKC pathway with the PKC inhibitor chelerythrine did not
prevent doxazosin-induced galectin-3 and collagen expression. Consistently, doxazosin
treatment did not alter total and phosphorylated PKC. These results suggest that
doxazosin-stimulated galectin-3 is independent of PKC pathway. To determine if the α1-
adrenergic pathway is involved, we pretreated the cells with the irreversible α-adrenergic
receptor blocker phenoxybenzamine and found that doxazosin-stimulated galectin-
3 and collagen expression was similar to controls, suggesting that doxazosin acts
independently of α1-adrenergic receptor blockade. Collectively, we show a novel effect
of doxazosin on cardiomycytes by stimulating heart fibrosis factor galectin-3 expression.
The mechanism of action of doxazosin is not mediated through either activation of the
PKC pathway or antagonism of α1-adrenergic receptors.
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INTRODUCTION
Doxazosin, a piperazinyl quinazoline compound, is a long lasting selective inhibitor of α1-
adrenergic receptors. It is a commonly prescribed treatment for patients with hypertension
(Black, 2003; Ceral and Solar, 2009) and enlarged prostate (Clarke, 1998). Doxazosin effectively
lowers blood pressure by blocking norepinephrine binding to α1-adrenergic receptors, relaxing
smooth muscle cells, subsequently decreasing vascular tone and reducing peripheral vascular
resistance. Doxazosin is also used to treat urinary retention problems in patients with
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benign prostatic hyperplasia. By blocking the action of α1-
adrenergic receptors, doxazosin treatment leads to relaxation of
the smooth muscles surrounding the prostate, which ease urine
flow and decrease bladder outlet obstruction (Tahmatzopoulos
et al., 2004). In addition, doxazosin has shown a beneficial
effect on lipids by modestly lowering both total cholesterol and
triglycerides (Remaley, 2007).
The utility of doxazosin for the treatment of hypertension
was called into question in March of 2000. A large national
prospective study ALLHAT (the Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial) sponsored
by the National Heart, Lung, and Blood Institute (NHLBI)
and conducted from 1994 to 2002 showed that compared to
the diuretic chlorthalidone, doxazosin was associated with an
increased risk of cardiovascular events, particularly congestive
heart failure (ALLHAT Collaborative Research Group, 2000).
Specifically, the study showed that the risk of congestive heart
failure was twice as high in the doxazosin group compared to
patients treated with the chlorthalidone. Thus, the doxazosin-
related portion of the study was discontinued. The increased risk
of heart failure caused by doxazosin might be due to the blocking
of specific receptors in heart muscle cells. Additional studies
have shown that doxazosin causes apoptosis in cardiomyocytes
and can arrest the cell cycle of human coronary smooth muscle
cells. However, these effects are independent of α1-adrenergic
receptors (Hu et al., 1998; Gonzalez-Juanatey et al., 2003;
O’Connell et al., 2006), indicating that doxazosin’s ability to
cause heart failure requires mechanisms that extend beyond
α1-adrenergic receptors blockade.
Galectin-3 is implicated in heart failure. This was first
reported by Sharma et al., who identified galectin-3 as the
strongest predictor of heart failure among 48 genes that
were upregulated in failing hearts compared to hearts with
compensated hypertrophy (Sharma et al., 2004). Several studies
have shown that galectin-3 is up-regulated in cardiac remodeling
and is a mediator of cardiac fibrosis (Sharma et al., 2004; Liu
et al., 2009; Yu et al., 2013). Galectin-3 knockout mice showed
decreased fibrosis and preserved cardiac function in response to
heart failure induction compared to controls (Yu et al., 2013). In
a clinical study of patients with heart failure, increased circulating
levels of galectin-3, used as a marker of cardiac fibrosis, were
associated with an increased risk for incident heart failure (Ho
et al., 2012).
We recently reported that activation of the PKC pathway
increases galectin-3 expression in cultured cardiomyocyte HL-1
cells. Moreover, we also showed that PKC-α promotes cardiac
fibrosis and heart failure by stimulation of galectin-3 expression
(Song et al., 2015). In the present study, we follow-up on the
findings of the ALLHAT trial by investigating the mechanisms
by which doxazosin used as an anti-hypertensive is associated
with an increase in clinical heart failure. We performed a
series of in vitro experiments to explore whether galectin-3 is
involved in the action of doxazosin on cardiomyocytes. We found
that doxazosin stimulated galectin-3 expression and collagen
synthesis in HL-1 cardiomyocytes. In addition, we found that this
effect did not require adrenergic receptor activity and was not
mediated by the PKC pathway.
MATERIALS AND METHODS
Cardiomyocyte Culture
HL-1 cardiomyocytes, kindly provided by Dr. Claycomb from
Louisiana State University Medical Center, were cultured
in an optimized Claycomb medium as previously described
(Song et al., 2015). Claycomb medium (Sigma, 51800C) was
supplemented with 10% fetal bovine serum (Sigma, F2442),
4 mM L-glutamine, 0.1 mM norepinephrine (Sigma, A0937) and
100 U/ml penicillin and 100 µg/ml streptomycin. Cells were
grown in culture flasks, dishes or plates pre-coated with 5 µg/ml
fibronectin (Sigma, F1141) at 37◦C in a humidified atmosphere
of 95% air and 5% CO2.
Chemicals and Cell Treatment
For pharmacologic cell treatment, HL-1 cells were grown
to confluence and serum starved for 12 h. The cells were
then treated with 0.01∼10 µM doxazosin (Sigma, D9815),
0.1 µM prazosin (Sigma, P7791), 2 µM PKC inhibitor
chelerythrine (Sigma, C2932), or 1 µM phenoxybenzamine
(Sigma, B019) for the indicated time. Doxazosin was
prepared as a 10 mM stock solution in DMSO and stored
at−20◦C.
Western Blot Analysis
After treatment, cells were lysed with an ice-cold modified
radio-immunoprecipitation assay (RIPA) buffer (150 mM NaCl,
10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1% Triton X-100,
1% sodium deoxycholate, 0.1% SDS, and protease inhibitors).
Cellular lysates were then centrifuged for 10 min at 10,000 rpm
and the supernatant was collected. Protein concentration was
determined by the Bradford method using BioRad protein assay.
Equal amounts of proteins (50∼100 µg/lane) were loaded and
separated by SDS-PAGE gels and transferred to nitrocellulose
membranes (Bio-Rad). After blocking with 5% non-fat milk
in phosphate buffered saline tween-20 (PBST), membranes
were incubated with primary antibodies overnight at 4◦C,
followed by horseradish peroxidase (HRP)-conjugated secondary
antibody. The protein abundance was detected using enhanced
chemiluminescence ECL system (Amersham Biosciences). Band
density was quantified using ImageJ software (National Institutes
of Health). The results were expressed as percentage of the
control group. The following antibodies were used in this
study: galectin-3 hybridoma (TIB-166; ATCC), Col Iα1 (sc-
8784; Santa Cruz), α-SMA (A2547; Sigma), PKC-α (sc-8393;
Santa Cruz ), PKC-α (phospho Thr497) (GTX61959; GeneTex),
PKC-α (phospho Thr638/641) (9375; Cell signaling), GAPDH
(sc-25778; Santa Cruz), HRP anti-rabbit IgG (NA934; Fisher),
and HRP-goat anti-mouse IgG (115-036-062; Jackson Immuno
Research).
Data Analysis and Statistics
The protein levels quantified by densitometry were expressed as
mean± SD. The statistically significant differences were assessed
by ANOVA with post hoc Tukey HSD test.
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FIGURE 1 | Effect of doxazosin on galectin-3 expression. (A) HL-1
cardiomyocytes were treated with doxazosin at doses of 0, 0.01, 0.1, and
10 µM for 12 h. (B) HL-1 cells were incubated with 0.1 µM doxazosin (Doxa)
or 0.1 µM prazosin (Prazo) for 12 h. Cells were collected and galectin-3
expression was analyzed by Western blot. Experiments were performed in





Galectin-3 is thought to enhance fibrosis, a central process in both
maladaptive cardiac remodeling and heart failure (Sharma et al.,
2004). To explore whether the antihypertension drug doxazosin
could influence galectin-3 expression, HL-1 cardiomyocytes were
treated with doxazosin at different doses for 12 h, and galectin-
3 expression was measured by Western blot. As shown in
Figure 1A, doxazosin stimulated galectin-3 protein expression
in a dose-dependent manner, with an initial increase seen at
a low concentration of just 0.01 µM. In patients, doxazosin
plasma levels of 122 nM are recorded at the therapeutic dose
of 8 mg (Frick et al., 1986). In addition, we examined whether
another quinazoline based alpha1 antagonist prazosin, similarly,
stimulates the expression of galectin-3. As shown in Figure 1B,
prazosin also stimulated galectin-3 protein expression in HL-1
cardiomyocytes.
FIGURE 2 | Effect of doxazosin on collagen I and α-SMA expression.
HL-1 cardiomyocytes were treated with doxazosin at increasing doses for
12 h. Collagen Iα1 and α-SMA expression was analyzed by Western blot and
data is shown as the mean ± SD (n = 3, ∗∗p < 0.01 compared to control).
Effect of Doxazosin on Collagen I and
α-SMA Expression
Increased interstitial and perivascular fibrosis are characteristic
of cardiomyopathy (O’Connell et al., 2006). Collagen I is one of
the major extracellular matrix proteins accumulated in cardiac
fibrosis. Additionally, the alpha-smooth muscle actin (α-SMA)
isoform is normally expressed in differentiating cardiomyocytes
and is a marker for myocardial hypertrophy in adult hearts (Kern
et al., 2013). We evaluated the effect of doxazosin on collagen
Iα1 and α-SMA expression in HL-1 cardiomyocytes. In Figure 2,
treatment of HL-1 cells with doxazosin for 12 h stimulated
collagen I α1 and α-SMA expression.
Doxazosin-Induced Collagen 1 and
Galectin-3 Was Not Affected by PKC
Blockade
Activation of PKC pathway promotes galectin-3 expression and
cardiac fibrosis in HL-1 cardiomyocytes and in heart failure
hearts (Song et al., 2015). Thus, we investigated whether PKC is
involved in mediating doxazosin-induced galectin-3 and collagen
expression. HL-1 cells were pre-treated with PKC inhibitor
chelerythrine (Chel) for 30 min prior to doxazosin treatment.
Inhibition of PKC did not block doxazosin-induced galectin-3
and collagen expression (Figure 3).
Doxazosin Does Not Change PKC
Protein Expression
Both clinical and experimental animal studies reveal the
association of PKC activation with cardiac hypertrophy and
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FIGURE 3 | Protein kinase C (PKC) is not involved in
doxazosin-stimulated collagen and galectin-3 expression. HL-1
cardiomyocytes were pre-treated with 2 µM chelerythrine (Chel) for 30 min
then treated with 1 µM doxazosin for 12 h. Galectin-3, collagen I, and PKC
were assessed by Western blot with appropriate antibodies.
heart failure (Bowling et al., 1999; Bayer et al., 2003). To
further investigate whether doxazosin affects the PKC pathway,
expression of total PKC-α was evaluated after doxazosin
treatment. As presented in Figure 4, doxazosin did not change
total PKC-α protein expression. By utilizing antibodies specific
for phosphorylated PKC-α, we assessed whether activated PKC-α
was altered even without changes in total PKC-α. However, levels
of phosphorylated PKC-α at Thr497, Thr638, and Thr641 were
not changed by doxazosin treatment.
Doxazosin Stimulates Apoptotic Protein
Caspase-3 Expression in HL-1
Cardiomyocytes
Apoptosis is recognized as a cause of interstitial fibrosis in other
organs (O’Connell et al., 2006). Doxazosin induces cell apoptosis
in prostate cancer cells (Garrison and Kyprianou, 2006; Forbes
et al., 2016) as well as in cardiomyocytes (Gonzalez-Juanatey
et al., 2003). Caspase-3 is a critical apoptotic molecule, as it
is responsible for the proteolytic cleavage of various regulatory
proteins, such as poly (ADP-ribose) polymerase (PARP). We
examined the expression of caspase-3 in HL-1 cardiomyocytes
in response to doxazosin treatment. As expected, doxazosin
increased caspase-3 protein levels (Figure 5), suggesting that
doxazosin similarly increases cellular apoptosis.
Doxazosin Stimulated Galectin-3 and
Collagen Expression Does Not Involve
α1-Adrenergic Receptor Activity
Doxazosin is a selective α1-adrenergic receptor blocker that
inhibits the binding of norepinephrine to the receptor on
FIGURE 4 | Effect of doxazosin on PKC protein expression. HL-1
cardiomyocytes were treated with 1 µM doxazosin for 12 h, total PKC-α
protein and phosphorylated PKC-α at Thr497, Thr638 and Thr641 were
analyzed by immunoblotting with appropriate antibodies. Experiments were
performed in triplicate and data is shown as the mean ± SD. Statistics show
no significance of doxazosin treated groups compared to control.
the cell membrane. To determine if α1-adrenergic receptor
activity is required for doxazosin-induced increase in galectin-
3 and collagen, we utilized phenoxybenzamine, an irreversible
α-adrenergic blocker, which permanently binds to α-adrenergic
receptors. HL-1 cells were pre-treated with phenoxybenzamine at
a concentration of 1µM for 4 h, followed by doxazosin treatment.
Blocking α-adrenergic receptors did not inhibit doxazosin-
induced galectin-3 and collagen expression (Figure 6).
DISCUSSION
Galectin-3 has been linked to interstitial cardiac fibrosis and
is a purported prognostic marker in patients with heart failure
(Sharma et al., 2004; Yu et al., 2013; Song et al., 2015). In the
present study, we found that doxazosin treatment stimulated
galectin-3 expression and collagen synthesis in cultured HL-
1 cardiomyocytes, suggesting a possible new mechanism of
doxazosin caused heart injury by stimulating heart fibrosis factor
galectin-3 expression.
Protein kinase C (PKC) is a group of serine/threonine kinases
involving many physiological and pathological processes. Animal
and human studies have revealed that activation of PKC-α
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FIGURE 5 | Doxazosin induces cell apoptosis in HL-1 cardiomyocytes.
HL-1 cells were treated with doxazosin at increasing concentrations for 12 h,
and the apoptotic protein caspase-3 was examined by Western blot.
Caspase-3 signals were quantified and is shown as the mean ± SD
(∗p < 0.05, ∗∗p < 0.01 compared to control, n = 3).
or an increase in PKC-α expression is associated with heart
failure (Braz et al., 2004; Liu and Molkentin, 2011). Inhibition
of PKC by ruboxistaurin attenuated diastolic dysfunction,
myocyte hypertrophy, collagen deposition, and preserved cardiac
contractility in a rat diabetic heart failure model (Connelly
et al., 2009). We recently reported that activation of the
PKC pathway increased galectin-3 protein expression (Song
et al., 2015). This prompted us to examine whether PKC is
the downstream target of doxazosin and mediates doxazosin
stimulated galectin-3 expression. However, our data did not
support an involvement of PKC in doxazosin-induced galectin-
3 expression and collagen synthesis. Neither did doxazosin
treatment alter the expression of phosphorylated and total
PKC-α.
Although doxazosin is an α1-adrenergic receptor blocker,
increasing evidence shows that doxazosin causes many side
effects unrelated to its α-adrenergic receptor blocking activity.
The anti-cancer activity of doxazosin is largely attributed to
apoptotic mechanisms. It has been shown that doxazosin
induced apoptosis is via a α1-adrenoceptor–independent
pathway (Kyprianou, 2003; Forbes et al., 2016). This was
confirmed by an elegant experiment showing doxazosin-induced
FIGURE 6 | Effect of α1-adrenergic receptor blocker on
doxazosin-stimulated galectin-3 and collagen expression. HL-1 cells
were pre-treated with phenoxybenzamine (Phen) for 4 h then treated with
doxazosin (Doxa) for 12 h. Galectin-3 and collagen I were analyzed by
Western blot. Signals were quantified as the mean ± SD (∗∗p < 0.01
compared to control without Doxa treatment, n = 3).
apoptosis in human embryonic kidney (HEK) cells lacking
α-adrenergic receptors (Thomas et al., 2008). In this study,
we investigated whether α-adrenergic receptor activity is
required for doxazosin stimulated galectin-3 expression.
Blockade of α-adrenergic receptors by pre-treatment of cells with
phenoxybenzamine did not affect doxazosin induced galectin-3
levels. This is consistent with a study by Ciccarelli et al. (2008)
showing that doxazosin stimulation of endothelial cell migration
and vascular tube formation does not require α-adrenergic
receptor activity and is independent of vasodilatation.
The mechanism of action of doxazosin might be very
complicated and is still under investigation. It has been reported
that doxazosin can enhance serum-induced extracellular
signal-regulated kinase (ERK) activation and phosphorylation
of Rb in endothelial cells (Ciccarelli et al., 2008). Garrison
et al reported that doxazosin induced apoptosis in prostate
cancer cells involves activation of transforming growth
factor-β1 (TGF-β1) signaling (Garrison and Kyprianou,
2006). An interesting study performed by Thomas et al.
showed that doxazosin only induced apoptosis in hERG-
expressing HEK cells, but not in untransfected control HEK
cells (Thomas et al., 2008). They propose that the potassium
channel hERG serves as the receptor for doxazosin which
may contribute to heart failure in patients treated with
the antihypertensive drug. By using HL-1 cardiomyocytes,
Eiras et al. performed a microarray analysis showing
an increase in phosphorylation of p38 MAP kinase and
focal adhesion kinase (FAK) in response to doxazosin
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treatment (Eiras et al., 2006). It will be interesting to know
whether p38 MAP kinase and/or FAK signaling pathways are
involved in doxazosin stimulated galectin-3 expression and
whether the increased heart failure risk by doxazosin is due to
activating specific receptors like hERG in heart muscle cells.
CONCLUSION
The major finding of this study is that doxazosin caused a dose
dependent increase in galectin-3 protein expression in HL-1
cardiomyocytes, a possible new mechanism of doxazosin induced
higher incidence of heart failure in the ALLHAT study. We also
found that the effects of doxazosin are not dependent on its
ability to inhibit the alpha-1 adrenergic receptor as an irreversible
antagonist was not able to block this effect of doxazosin.
Further studies are needed to elucidate the intracellular signaling
pathways mediating doxazosin-induced galectin-3 upregulation
in cardiomyocytes.
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